The IDEO team quickly discovered that the challenge of designing a Digital@FEMSA super app for tens of millions of customers was matched only by the operational complexity of bringing together different teams that had already created various apps with separate value propositions. Not to mention the 22,000 stores specifically tailored to local communities.

To kick off the project, the IDEO team built on FEMSA’s already deep understanding of its customers by meeting them in their homes and communities. The team discovered that users didn't care about long-term rewards; instead, they wanted everyday help to thrive long-term. Connecting omnichannel rewards to regular spending would allow them to save time and money—something they said was particularly important. Along with market research, insights like these directly informed the app's design, ensuring that it was compatible with users' everyday habits and preferences.

Meanwhile, the project team also worked to ensure the app fit the priorities of the various teams inside Digital@FEMSA, designing a comprehensive process for testing joint value propositions. Together, the team created a new design system, iconography, and set of unifying principles. IDEO also worked closely with the Digital@FEMSA teams to ensure that the app's design was in line with their strategic goals and technical capabilities, and built the app's initial information architecture. They incorporated secure transactions, effortless coupon redemption, personalized offers, and a cohesive loyalty program.

From there, the IDEO and Digital@FEMSA teams quickly transitioned into the design and development phase, producing prototypes of the new app, dubbed Spin Premia. With the help of user testing, they were able to continuously iterate to improve the app's features and functionalities, creating a user experience that was both seamless and intuitive. In just 10 months, they went from a small digital team with an ambitious idea, to a 150+ people product organization and an MVP launched in one region. And thanks to a tight partnership, the teams were able to seamlessly integrate Spin Premia into Digital@FEMSA's existing systems, resulting in a scalable implementation nationwide just a few months later.

The introduction of Spin Premia was a milestone in FEMSA's digital transformation path. Following a true ship and iterate model, just a few months into the project, the company released a smaller, focused version of the app in just one city in Mexico to quickly learn from customer experience before expanding to new regions. Since then, the Spin Premia app has quickly gained popularity, offering a safe and user-friendly platform that millions of Mexican consumers have embraced. It has also allowed FEMSA to broaden its digital portfolio and extend its customer base throughout Mexico, elevating customer satisfaction and fueling business expansion.

13 million Mexicans visit FEMSA’s OXXO convenience stores every day. But the company had ambitions to leverage digital experiences to increase customer engagement.

‍

To get there, Digital@FEMSA needed to deliver exceptional digital products with the agility to serve an entire population.

4.7 stars

Spin Premia’s app store rating

22.8 million

active Spin Premia program users

‍

Midscale hotel brands are the fastest-growing hotel segment in the US, attractive to both travelers and hotel owners. But often, their messaging feels repetitive, and travelers have a tough time differentiating between them. With a warm, thoughtfully designed midscale brand, IHG had an enormous opportunity to distinguish itself in a crowded market. 

IHG’s goal was to deliver a guest experience that felt genuinely unique and resonant—and quickly. With costs on the rise, many owners were motivated to turn toward conversion brands, which allow them to refurbish hotels under a new brand rather than invest in construction, a way to grow their portfolio in a tight financing market. Meanwhile, IHG’s competitors were set to introduce new conversion brands of their own. The company was looking for a partner that could work swiftly and iteratively to deliver a distinct brand.

For the IDEO team, the answer lay in communicating the brand’s value, starting with a custom logo rendered by hand. Inspired by vintage sign painting and modernist typography, the team sketched different versions of the letterforms, reviewing them with IHG until they had a set that brought to life the generosity and sense of invitation associated with the hotel’s spaces. They also worked to ensure the wordmark was visually balanced and would translate well across a variety range of scales. From there, they built an expansive brand world, including bespoke navigation icons, a full interior and exterior signage system, and a video to support the Garner launch.

The result is a hotel brand that stands apart in its category for both travelers and owners: thoughtful and well-designed yet affordable. As competition in the midscale segment continues to increase, Garner has been central to IHG’s growth strategy. Launched in the fall of 2023, Garner opened 100 hotels worldwide in just 16 months, making it the fastest-ever IHG brand to scale globally. The brand’s increasing popularity among owners and developers is driven by the growing demand for conversion properties, which accounted for 52% of IHG’s room openings in 2025. Garner plans to continue its rapid expansion with nearly 80 additional hotels in 12 key markets, including the US, Mexico, Italy, and Japan.

Conversions account for 12% of the global hotel pipeline, enabling hotels to switch brands and refurbish, boosting revenue without expensive construction.
‍

The US midscale hotel segment, valued at $14B, is expected to reach $18B by 2030.

100 new Garner Hotels

in less than 3 years—the fastest-scaling brand in IHG's history

500 Garner Hotels

planned in the next 10 years; 1,000 over the next 20

Alzheimer’s and dementia are notoriously difficult to treat—and scientists estimate that some 50 percent of people who have dementia are undiagnosed. Recognition of symptoms and early intervention are key. Together and IDEO set out to conduct user research to inspire new products that would help patients with cognitive decline take charge of their brain health.

The first priority was to expand the reach of the Moving Together program, which combines group movement exercises with mindfulness techniques, led by a trained group instructor. The IDEO team conducted remote and in-person interviews in Florida, where one in five residents is age 65 and older, and rates of Alzheimer’s and dementia are among the highest in the country. One of the key insights the team discovered was that many older adults didn’t understand how behaviors like smoking, exercise, and diet can be risk factors for cognitive decline. Their input inspired a new design principle for the program: “No naked feedback.” Any time participants received health coaching advice about modifying their lifestyle, they would also be given resources on why and how to do it, so they would have a pathway to boosting their brain health. 

The IDEO team folded insights like this one into the design for four new product offerings, including personalized brain health education, new online community engagement tools, partnership programs, and health coaching services, as well as a new user interface to illustrate them. Along with Together they also developed an implementation roadmap of next steps to bring the new digital product offerings to market, such as hiring a brain health coach and creating a new course curriculum. Now, Together has enrolled 165 people in the Boost Your Brain Health Clinical Trial, which is looking at outcomes such as reduced risk of Alzheimer's and maintenance of cognitive function for the Brain Health Together program. With trial completion in Q3 2024 and product launch in early 2025, growing numbers of people with MCI will have access to this exciting program. Together incorporated almost all of the elements from the IDEO roadmap into the final curriculum, and the team often refers back to insights the team gathered as guiding design principles.

Fighting barriers to diagnosis

With its online program growing, Together wanted to take on an even bigger problem: dementia underdiagnosis. Co-founder Dr. Deborah Barnes had recently developed an algorithm that uses patients’ health records to calculate their risk of undiagnosed dementia, called the electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR). Together was looking to find creative ways to equip and empower providers to use risk scores like eRADAR in primary care settings.

One piece of the puzzle? Many primary care doctors are unaware that better management of Alzheimer’s disease and dementia can have a positive impact on other chronic health issues—like diabetes, hypertension, and depression. So by encouraging providers to prioritize dementia care, they can help support the overall health of older adults with cognitive decline. The IDEO team recommended a curriculum for continuing education courses for doctors that make that link clear—another step toward increasing dementia diagnosis and improving overall health.

‍
Better help, sooner

To understand the patient experience, Together and IDEO decided to work directly with patients and caregivers to uncover what was stopping them from asking for dementia screening. The IDEO team quickly learned many patients were afraid of facing a diagnosis that signified a loss of agency and control, especially when they didn’t believe there were good treatment options. Often, they were unaware that there were things they could do to improve their brain health. They needed to know what steps to take after a diagnosis, and who could provide actionable advice. In response, the IDEO team designed a digital activity toolkit and physical booklet to guide patient families through the early stages of a dementia diagnosis, including recognizing the signs and symptoms, having better conversations with their doctor, and getting connected to support groups and programs like Moving Together.

Solving the problem of dementia underdiagnosis involves complex systems-level thinking and designing for the entire health ecosystem of patients, providers, and insurance payers, and solutions for Alzheimer’s and dementia care are still in their infancy. But already, this work is empowering patients and doctors to prioritize brain health and get screened sooner, and Together, which has since been acquired by Linus Health, is still working to move dementia care forward.

Approximately 12-18% of people aged 60 or older live with mild cognitive impairment, while memory loss, Alzheimer's and dementia affect more than 50 million people around the world.

‍

An estimated 50% of people living with dementia are undiagnosed.

165 enrolled

in the Boost Your Brain Health Clinical Trial

Many companies view culture-building initiatives as nice-to-haves. At Moderna, Mindsets are a business imperative, crucial to its plans to develop breakthrough products quickly.

For companies working on solutions as vital as a COVID-19 vaccine, delays and mistakes don’t just mean missing a product launch date—they’re life-or-death, and on a large scale. Moderna had to ensure that its employees knew how to make the right decisions, evaluate risk, and move quickly—even if they came from organizations with more bureaucracy and less risk tolerance. In 2021, IDEO sat down with longtime Moderna veterans to hear stories about moments that exemplify the company's culture, like the day a critical piece of equipment arrived but was too big to fit through the door. Taking it apart would have added days to their timeline. So employees took sledgehammers to a wall instead. Stories like this one fed into the crafting of the list of Mindsets, such as “Act with urgency: Action today compounds the lives saved tomorrow” and “We behave like owners: The solutions we’re building go beyond any job description.”

To gather feedback, the team shared the draft Mindsets with a diverse set of employees—new hires, veterans, folks already closely aligned with the culture, folks for whom it wasn’t the most natural fit, and a plethora of employee resource groups. CEO Stéphane Bancel and the leadership team took crafting and iterating on the Mindsets very seriously, wordsmithing and tweaking them with the team until they were ready to share them officially. Now, new hires learn about the company’s Mindsets in Moderna ONE, an onboarding process that IDEO helped revamp, while existing employees attend a workshop to ensure everyone at the company knows not only what to do but also how to do it effectively. In a matter of weeks, IDEO helped Moderna codify its culture for employees and set the company up for continued success. Moderna continues to embed these Mindsets across the entire employee lifecycle to systematically scale its culture.

For employees new and old, the clarity of the Mindsets has made it easier to understand expectations and to understand the company itself. Long-term veterans responded with comments like, "These really help explain why we're working this way,” while one newbie said, "It feels like a homecoming to hear the culture that we’re trying to bring through.” But more than just solving a cultural issue, the new Mindsets have fulfilled a business imperative: Holding on to the secret sauce that made Moderna successful to begin with, setting the stage for its next five years of breakthroughs.

When the World Health Organization (WHO) declared the COVID-19 health crisis a pandemic in March of 2020, Moderna had fewer than 1,000 employees. Four years later, it’s more than five times the size.

Ranked #1

BioSpace Best Place to Work, large company in 2024

Ranked #6

Boston Consulting Group’s 50 Most Innovative Report in 2023

Ranked #4

Deloitte’s Technology Fast 500 List in 2023

For decades, women’s health has been underfunded, overlooked, and too often reduced to reproductive care. Medical research has been built around male bodies, while the complexity of women’s biology and lived experiences has been treated as a problem to simplify rather than an opportunity to understand.

Now, AI could change that. Designed intentionally, AI could unlock new kinds of evidence that close historical data gaps and inform better care. But if we aren’t careful, we could be scaling systems that were never designed for women and build the next generation of healthcare on the same broken foundations as the past.

The stakes are high. The opportunity is massive. This is where design matters most.

Introducing the Women’s Health × AI Exchange

We believe design can help us embrace AI’s healthcare possibilities while recognizing and mitigating its risks. And we believe the most promising futures are shaped collaboratively, by bringing different perspectives into conversation and making those possibilities tangible.

That’s why we’ve launched the Women’s Health * AI Exchange, an open, design-led exploration of one important question: How might AI meaningfully transform women’s health, and what would it take to ensure that it does?

To frame this exploration, we crafted six provocations about possible futures at the intersection of women’s health and AI. Futures where AI could:

• Reframe women’s biological complexity from a healthcare liability to a scientific asset and create new pathways for better care.
• Transform the relationship between healthcare professionals and patients, translating qualitative data into clinically actionable evidence.
• Connect the dots across a woman’s health journey to enable more proactive, preventive, and life-stage-specific care.
• Drive innovation in women’s longevity, helping researchers understand what most influences how women age.
• Flip the economics of clinical research, incentivizing exploration at the deprioritized edges and intersections.
• Put data back in women’s hands to help them find their own insights around issues where institutional research has not been prioritized.

Imagining what AI could do is only half the work. We also need to consider the shifts required to make these futures possible. And so, each of these provocations ends with the same challenge: What would it take to make them real? 

We’re inviting you into this conversation to help us collectively sharpen a point of view and co-design a landscape of opportunities. Here’s how to join.

Go to the Women’s Health x AI Exchange and choose a provocation that resonates with you. An AI facilitator will ask thoughtful follow-up questions to help you frame your point of view and articulate what you believe needs to change. Your thoughts will be posted anonymously. As more people participate, their contributions will help reveal where perspectives align, where tensions remain, and what new opportunities are emerging.

Turning tension into possibility

This conversation is just the beginning. We’ll synthesize themes and share emergent opportunities. We’ll bring together people across healthcare, research, technology, investment, and design to help us prioritize opportunities for further exploration. And we’ll translate the most compelling ideas into tangible prototypes that help people see, experience, and shape what desirable, viable, feasible, and responsible AI-enabled healthcare could look like.

We’re approaching this as an investigation in motion, not a finished thesis. Our intention is to work openly so the perspectives, provocations, and possibilities we generate can inspire and inform the people already working to move women’s health forward.

And while women’s health is at the center of this exploration, the conversation we want to have is even bigger. It is a conversation about the future of healthcare data and power. A conversation about how AI might help close the gaps that decades of underfunding have left behind, and what we can all do to ensure it does.

Whether you’re a clinician, researcher, technologist, entrepreneur, investor, designer, or simply someone who cares about the future of healthcare, we invite you to help us reimagine what healthcare could be, for everyone.

Explore the Women’s Health * AI Exchange and add your perspective.

‍

‍

AI is transforming healthcare at a remarkable pace. But our understanding of women’s health has a lot of catching up to do.

During a recent meeting with a pharma client, we played a YouTube video of GLP-1 users that left the team slack-jawed. Sitting around a conference table, they watched people crack open an auto-injector and pour the contents into a vial so they could titrate out a more precise dose of the drug themselves. They heard several patients admit to using a family member’s prescription because they didn’t have their own. Others lamented that they weren’t in range for their preferred direct-to-consumer delivery platform. The realization was stark: patients knew what they wanted from their GLP-1s, and if the manufacturer didn’t provide it, they would find a way to make it themselves. In that moment, this particular pharma company understood it was not at all prepared for a future where patient expectations would remake the drug market. 

The introduction of Ozempic and new access models for GLP-1s like Lilly Direct and Hims & Hers have fundamentally shifted the pharmaceutical industry in the last five years, unleashing more self-directed therapy journeys and a new kind of healthcare consumer. Patient expectations about what pharma companies can do—and the experiences available to them in a healthcare setting—have been completely rewritten. This revolution is making traditional pharma commercialization processes that push patients and providers through a few preferred channels a thing of the past. Especially as consumer-facing startups come for their market share—and create an even larger pie.  

If pharma companies are going to meet this new wave of consumer expectations for everything from GLP-1s to hair loss and erectile dysfunction medicines, supplements to fertility drugs, they need to prioritize designing exceptional experiences that come along with their therapies. That requires building an entirely new set of skills and behaviors that can support product pipelines. Here are four crucial steps to get there.

1. Uncover the needs patients want pharmaceuticals to meet

Pharma companies need to do research with real patients to get a clear view of the full therapy journey—from diagnosis to long-term use. In that process, they can identify the highest-risk moments, like confusion over instructions, frustration over delivery methods, and potential misuse, and prioritize opportunities to improve real-world adoption and adherence. 

Lilly understood this early on. In the 1990s and early 2000s, the pharma company had several new, life-changing medications and two big challenges: Its primary drug—insulin—had to be self-injected, which patients were hesitant to do. And its drug-delivery device platform lagged behind the needs of insulin users.

Lilly approached us to design the next-generation auto-injector platform. Early in the partnership, a team of IDEO designers and Lilly leaders met with diabetes patients around the globe to better understand how they lived with the disease. They quickly realized there was a need for a device that met the needs of a broad range of dexterity-challenged and injection site-specific patient populations (including rheumatoid arthritis and psoriasis patients). As the development of multiple candidate molecules was still underway, the team focused on creating an injection experience that would work for these more challenging patient populations, knowing that a design that worked for them would also deliver a better experience for a broader swath of future users. 

While we carefully considered every feature of the autoinjector itself (from grippy labels and a stable, twist-off base to large, clear unlock tabs and injection buttons), we also designed packaging that fit in a standard-sized refrigerator, created a set of highly visual instructions, and took into account the involvement and support of family members and caregivers. 

Fast forward to 2026, and Lilly is still leveraging the design we made together to not only support pre-diabetes treatments like Trulicity, but also psoriasis therapies like Taltz, migraine therapies like Emgaility, and GLP-1 molecules like Mounjaro and Zepbound. The latter accounted for the majority of the company’s annual revenue in 2025. Taking the time to create a comprehensive drug delivery experience has yielded an invaluable delivery toolkit that Lilly and the patients they serve still benefit from today.

2. Design the experience around the therapy

As more and more pharma companies create consumer-style experiences, it’s crucial they build services and tools that support onboarding, adherence, and ongoing use. Standing out is no longer just about drug efficacy. It’s about how well patients with all kinds of needs and circumstances can access and adhere to the therapy—and how well pharma companies can deliver against their competitors. 

When Sanofi launched Beyfortus, the first-ever RSV immunization for newborns, in 2024, it was a milestone in the fight against the virus, which had resulted in the death of 445,000 babies worldwide in 2019 alone. But the company knew that growing anti-vaccine sentiment might prevent parents from giving their children the potentially life-saving immunization. 

Together, we conducted research with parents, caregivers, healthcare professionals, and healthcare administrators in Germany, Spain, China, and the US to identify barriers to adoption across cultures. The team quickly discovered that no single approach would work across Sanofi’s 20-plus international markets. Training for medical professionals needed to be flexible and customizable. They also discovered that discussing immunizations right after a baby was born was too stressful for new parents.  

Ultimately, the team created an accessible global communication toolkit with straightforward language, metaphors, and illustrations to support informed conversations between providers and parents before and after a child is born. Then they held a series of market-fit co-design workshops to make the tools more resonant with regional customers and ensure compliance with local regulations.

In its first year on the market, Beyfortus became a $1.8 billion therapy, and more than six million babies have been immunized. 

With a growing funnel of information about drugs, therapies, and even supplements, pharma companies must cut through the noise to support patient understanding and adherence. 

3. Define how you show up beyond the drug

To have an even greater impact on patient outcomes, pharmaceutical companies should explore new roles, partnerships, and models. That could mean creating new offerings that combine a given therapy with support and services, building partnerships with payers, employers, or platforms to extend reach, or creating models that tie therapies to long-term outcomes and value.

Japanese pharmaceutical company Otsuka is perhaps one of the most diversified pharma organizations in the industry, focusing on above-molecule interventions including companion diagnostics, digital technologies, and other tools that enhance the effectiveness of chemical or biological treatments. With a business that spans traditional drug development and manufacturing, digital solutions, and even consumer products such as Pocari Sweat, an electrolyte drink, Otsuka has bet that diversity and go-to-market pathways will lead to better experiences for patients. Not to mention these touchpoints also provide deep insights into the needs of the people Otsuka serves. 

In 2018, Otsuka joined forces with Click Therapeutics to develop digital health services to accompany one of its leading medications, aripiprazole. The antipsychotic is used to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD). By 2024, the company had developed an app featuring activities aimed at treating MDD. The partners chose a challenging but potentially impactful area for their pilot program: four primary care sites within the National Health Service (NHS) in the UK with a high caseload of MDD patients, where a digital solution combined with antidepressants could significantly reduce the burden on these sites.

Depression is widespread across the UK, and the treatment demands on the NHS are considerable. However, the system lacks the resources to provide every patient with the necessary services to treat their conditions. This digital companion to antidepressant medication aims to improve treatment effectiveness, and if the pilot is successful, it could significantly ease strain on the NHS while helping patients achieve better outcomes. 

4. Create a human-centered R&D pipeline

Creating more human-centered packaging or instructions to help people better understand a drug is an effective step forward, but exploring new internal capabilities that make your innovation pipeline more future-fit and human-centered can be transformative. 

That work can take many forms: building a beacon project that upskills product and team leadership on methods to better understand the decisions consumers are making today and in the future, introducing futures-thinking to help your team look beyond the next five years, or reinforcing purpose and culture to empower employees to make patient-centered decisions. 

In 2020, as Moderna raced to deliver a COVID-19 vaccine during the pandemic, the company needed to grow exponentially—and rapidly. However, by hiring employees from traditional pharma giants, it risked losing the unique entrepreneurial culture that made it successful in the first place—one that embraced speed and accepted risk. This shift could have limited its future ambitions of developing breakthrough products to combat other viruses and diseases, and even cancer. 

Together, we worked to codify the company’s culture and values into a set of Mindsets that would empower employees to move quickly, evaluate risk, and make the right decisions. The team met with Moderna veterans to gather stories about key cultural moments, like when a crucial piece of equipment didn’t fit in the door, and employees knocked down the wall to keep vaccine production moving. Insights from these stories became Mindsets, like “Act with urgency: Action today compounds the lives saved tomorrow” and “We behave like owners: The solutions we’re building go beyond any job description,” that were then tested with new hires, employee resource groups, and others across the company.

The Mindsets were more than a tagline: they set the stage for continued progress and future breakthroughs. Today, Moderna is working with Merck on a cancer vaccine that just completed a successful Phase 3 clinical trial.  

This sea change in consumer expectations for medicines and therapies can feel disorienting for traditional pharma companies—but it also offers enormous opportunities for those that think outside tried-and-true drug delivery channels and embrace human-centered design. By truly understanding patient needs, finding new and inventive ways to support them, and building the capabilities to empower your people to create a human-centered R&D pipeline, organizations can distinguish themselves in the market. These behaviors can not only drive the market, but more importantly, radically improve patient outcomes. 

“This sea change in consumer expectations for medicines and therapies can feel disorienting for traditional pharma companies—but it also offers enormous opportunities for those that think outside tried-and-true drug delivery channels and embrace human-centered design."

A pioneer of human-centered design at IDEO, Jane Fulton Suri joined one of IDEO's predecessor firms, ID Two, in 1987. With a background in psychology and architecture, she gained early experience as a researcher at the renowned former Institute for Consumer Ergonomics at Loughborough University of Technology. At ID Two, and later at IDEO, Suri introduced social science principles to the design industry, which had not yet fully embraced them. Her contributions would go on to reshape the field.

Suri’s influential 2005 book, Thoughtless Acts?: Observations on Intuitive Design, features a collection of snapshots that highlight the subtle, instinctual ways people interact with the everyday world. It’s a love letter to observation as a design discipline with real-world impact. Her work in human factors at IDEO has influenced products people use every day, from rubber grips on Oral-B toothbrushes to redesigned Evenflo strollers. In recent years, she’s expanded her focus beyond human-centered design to explore how patterns found in nature and living systems can inspire more sustainable solutions—what she calls life-centered design.

Now a Partner Emerita, we were so glad to welcome Jane back to IDEO earlier this year for a conversation with our design community. 

Mike Peng (MP): If you don’t mind, Jane, tell us about your origin story and how you came to IDEO. 

Jane Fulton Suri (JFS): I started out in psychology because I was really interested in people. And then I got really interested in people in the everyday world. I brought that mindset into design: Let’s get out there and see what people really do. 

I found myself working with manufacturers to help them understand why people didn’t do what they expected them to with power tools, motorcycles, and other dangerous things. A lot of my work was mitigating disaster. And I thought, this is crazy. Why aren’t these conversations happening while things are being designed? Problems are easier to remedy at the design stage than when they’re on the market.

Then I met Bill Moggridge, one of IDEO’s three cofounders, because a friend of mine was his client. He was a myth and a legend. After our conversation, he asked me, “What do you want to do now?” And I said, “I’d like you to offer me a job!”—which was very, very uncharacteristic of me. I had no clue what I was getting into.

I quickly realized I needed to understand what my teammates were doing and value that, then add ideas about going out, meeting people, and watching what they do.

So instead of having the answer, I realized the point was about discovering together how to make the design brief better. That became the practice—getting away from the desk. And now that means teams getting away from their screens and going into the world together.

MP: Now user research and ethnography are common practice in design. What were the early days like?

JFS: When we started out, we had no budget for anything I wanted to do. I had to convince my colleagues it would be exciting and interesting, and that we’d have good stories to tell our clients. Then it became a bit of a sales story about why it might take an extra week or two, or even a month, to do the project.

What we were doing was more like exploration; we didn’t know what we'd find, and afterward, we would probably want to do something different from what we’d promised when we wrote our proposal. 

MP: If you had to sum up a few of your most memorable projects while you were at IDEO, what are some of the ones that really stood out to you?

JFS: Early on, Supercuts invited us to bid on an innovation-focused job. At the time, we were essentially a product design company. David Kelley, Tom Kelley, and others weren’t sure what we might do for a company like Supercuts.

So with one of the other early human factors researchers, we went out and got haircuts. Then we went around the city just looking at different hair stylists’ establishments. We started putting together a story of how customers make decisions from the moment they think about wanting a haircut to deciding where to go, making their first appointment, then all the behaviors that follow, like primping a bit before you leave the shop. 

We had a lot of fun engineering this great crazy clipper. But I always believed our best ideas were these little moments throughout the experience, like getting a cape that made you look good, or a mirror that said “Supercuts” so you’d remember where you were. That was our first customer journey map.

MP: Are there other memorable moments that really stick out to you?

JFS: One of the most moving ones for me was at IDEO Chicago, years and years and years ago, when colleagues of mine were working on the LifePort Kidney Transporter. The project was all about how precious a kidney is. The team described their experience in the operating theater, seeing the surgeon take this living element and cup it so gently, like a baby bird, as he transferred it to where he needed to place it. That recalibrated the team’s thinking about designing the carrying system, because we’d just been thinking about it functionally and mechanically. But it also let them tap into what it really means to design for a living passenger. 

MP: Let’s dive into the craft of design research. How do you know when a research insight is truly great?

JFS: Insight, for me, is a change of state in our understanding. There's an epiphany of sorts, a new recognition. You get an insight by being a sensory human being, observant and absorbent through all your senses…and then discovering you are excited about something new. Design and innovation take a lot of personal energy. That human emotion has to come from you.

And that’s what happens when clients get really drawn into ideas, too—they feel you’re changing the way they see things. 

MP: What fundamentals do we need to continue to embrace to do research well?

JFS: Nothing beats being an aware, sensory human being who is curious about other people, places, and things. Research doesn’t have to be expensive. Even a conversation with one interesting person, or exposure to an unfamiliar place, will do.

Sometimes we're reluctant to put something in front of the client that we think is a really cool idea, but nobody has said they wanted it. Perhaps the research didn’t show that it was a really good idea yet. But sometimes we have to have conviction about our own perspectives and the confidence to share innovative ideas, even without hard evidence. I’ve always felt that. 

MP: One of the most important phases of IDEO’s design-thinking process is synthesis—taking the messy materials we’ve gathered during research and making sense of them. How do you approach synthesis?

JFS: I once wrote a piece about how what happens in the design process isn't the same as how we formally describe it. One story stands out. I call it “the black shoes.”
‍

‍Annette Diefenthaler, now Professor and Executive Director of the Munich Design Institute, was an IDEO researcher working with a global bank trying to set up a presence in Russia. The team had done loads and loads of interviews with people about banks. Late one night, on the way back to their hotel, Annette saw a big shopping center. She asked the driver to stop, because she realized they'd had no time, other than doing their interviews, to absorb much about the culture.

So she went into this big mall, and Annette was stunned by how simply the department store had arranged its products. One wall was just black shoes all lined up, all the different kinds of black shoes you could have. It was all really obvious and not very exciting because there were only black shoes—no glitz at all.

What she took from that was: this is a culture where trust is built by showing what there is. It was so honest and direct. And here we were, talking to all these people about banks and trying to understand how to build trust in an alien brand. She had a flash of insight that suddenly made sense of what the team had been hearing. The bank needed to be so much more straightforward and transparent about its services. “Black shoes” became a mantra for that project and shaped how they designed the bank’s interior and described its offer.

This insight came from a moment that was completely off script. I love that. You can’t always get to an insight by staring at your interview notes. You get it because it’s somehow gotten into your viscera.

MP: Are there any moments where you found creative ways to present research to clients to help them make decisions?

JFS: Instead of personas and customer descriptions, a team once created a series of packed suitcases that represented the different types of travelers they interviewed. The client loved that one.

MP: How do you find the courage to decide to deliver an installation of suitcases instead of a more traditional research deliverable, like a presentation?

JFS: You need to tune in to what your client needs to absorb and what you want to communicate, and be ready to experiment with how you do that. You need to get good at failing. You try things, fail, and learn how to gauge what might work better the next time. 

MP: You’re an incredible artist—I’ve seen your woodblock prints. You’re also an amazing rock climber and swimmer. I’m curious how these activities helped you develop your craft as a researcher and a designer.

JFS: There’s something very elemental about all of them—they’re direct experiences of the world. You give your weight over to the rock. You trust the water. Even with woodblock printing, what I love is how material it is. I use sharp knives and gouges to carve the wood, then I learn how much water and ink to use and how the brushes work. 

That’s the thing I find really exciting. The fact that human beings have evolved to make beautiful things, that connection of making and place is a crucial motivator.

MP: You are one of the authors of the first edition of The Little Book of Design Research Ethics. I’d love to hear your perspective on the ethics of the discipline, and what we should keep in mind as we increasingly rely on technology. 

JFS:  I have a problem with the term research, partly because I think it connotes things like clipboards and taking notes—that we’re documenting other people’s lives. I’m happier when it all feels more like co-discovery, exploring together. We are together, engaged in this space, noticing things about your behavior as well as what I’m thinking about your behavior. And it's more collaborative.

 Co-discovering with other humans is a much nicer place to be.

MP: Looking back, knowing what you know, what advice would you give young Jane? 

JFS: I think I had imposter syndrome for about five years or so. I could have moved along a lot faster if I’d had a little bit more confidence and maybe a few more people telling me that it was okay. 

MP: Are there any insights from your human factors work that you apply to the broader scope of life-centered design, and how we can learn from that?

JFS: A human being is a living thing in a living system of other living things. Observation and curiosity are key—we should keep asking the same kinds of questions about the inherent behavior of those systems, as we would ask about people: what they really do, what motivates them, and how we can gain insights from them. This goes back to your question about how rock climbing, swimming, and art come into it, in the sense that we can think more broadly about the elements that matter to people. There’s a whole living world out there with great examples of elegant systems we can learn from.

‍

This Q&A has been edited for length and clarity. 

‍

“Insight, for me, is a change of state in our understanding. There's an epiphany of sorts, a new recognition. You get an insight by being a sensory human being, observant and absorbent through all your senses."

When category-defining challenges like disruption, the accelerating pace of change, and the need to rethink how organizations work are on the table, looking back on the current year and fighting for the same budget won't work. That's why many of the leaders we partner with are massively rethinking their priorities and where to best focus their resources. 

It’s a lot to balance, but the process doesn’t have to feel like guesswork. For several years, we’ve been using a tool we call the Planning Canvas, which provides a clear, strategic, and uncomplicated way to reflect on what has changed, what you’ve learned, and what matters now before planning for the coming year. It’s a simple way to help you evaluate where you are, and what levers you might pull to get your organization where you want it to be.

Download the Canvas

Our 2027 Planning Canvas walks you through three effective steps: 

1. Reflect on what’s changed
2. Imagine the impact you want to have in the near future
3. Decide what to double down on, reform, let go of or pursue as a new bet

We recommend using it for individual reflection ahead of annual planning, before team sessions and leadership decision meetings begin. It will help you arrive with a clear point of view on what has changed, what matters now, and the choices worth putting on the table. At the same time, don’t hesitate to adapt it to your needs. If facilitating a collaborative conversation across your team aligns better with your organization's culture, this tool can help with that, too.

The goal isn’t to predict the year ahead perfectly. It’s to enter planning conversations with a sharper point of view and the confidence to make impactful choices together. We hope you find it useful. 

Looking for more help with strategic challenges? Get in touch. We’d love to connect.

‍

At a time when uncertainty feels like a constant, leaders across categories can find it tough to make confident planning decisions for the year ahead.

As a former IDEO client, I saw firsthand the power of design to inspire positive change within the world of finance. Now, I’m a Partner and head of the financial services practice, where my work is stitched together by a common thread: As finance increasingly becomes digital and decentralized, as demographics and attitudes change, and as weighty questions about our climate future and tackling inequity arise, many of the clients I work with are facing tremendous threats to their current ways of doing business—but also tremendous opportunities.

I build deep relationships with banking, wealth management, fintech, and insurance clients of various scales and at various life stages and help them grow new muscles.

Prior to joining IDEO, I served as senior counselor to now-U.S. Senator Elizabeth Warren and as the first Assistant Director for Consumer Engagement at the Consumer Financial Protection Bureau, where I led brand management, digital strategy, and consumer experience.

For more than 10 years, I have focused on cultivating craft and content excellence at IDEO Shanghai, helping creative leaders and courageous clients do career-defining work together. I partner with multinational and Chinese organizations across industries, using human-centered design to drive category growth, develop innovation capabilities, and launch new brands and products. And I am passionate about developing talent that has the ability to deliver culturally-relevant and strategically-impactful work across cultures.

My clients have included companies like Volvo, IKEA, Nike, Shinho Foods, Envision Energy, Ford JMC, Fotile Kitchenware, L’Oréal, CR Land, John Deere in India, and Intercorp in Peru. I have spoken at events hosted by ChinaAccelerator and the Innov8rs Conference in Shanghai.

Prior to joining IDEO, I worked as a Creative Director focused on brand strategy and brand identity systems in France, the UK, and Vietnam. I hold a Master’s Degree in Visual Communication from Olivier de Serres, Paris, and a Master’s Degree in Creative Practice for Narrative Environments from Central St. Martins School of Art and Design, London.

My portfolio of work is focused on transformation strategy for platform businesses by growing capabilities, developing product strategy, cultivating change, and pushing the edges of media and technology. I have cultivated key relationships and nurtured business partnerships to develop a multimillion dollar, industry-facing consulting portfolio and have designed products, strategy, and experiences that have become category leaders.

I am passionate about developing practices and capabilities that uniquely bridge design strategy and developing new products and services while accelerating transformation to create future-fit organizations.

I bring expertise from previous careers in architectural design and luxury hospitality operations. I hold a Master of Architecture degree from California College of the Arts. In addition to my design and leadership practice, I have taught courses in interaction design, architecture, film, and creative leadership, and have guest lectured at the University of California at Berkeley, California college of the Arts the d.school at Stanford, and The School of the Art Institute of Chicago.

As a Partner and Managing Director for IDEO’s Play Lab, I drive the growth of the Play Lab’s business, the strength of our partnerships, the delivery of our work, and the growth of our people.

As a champion of the power of Play in addressing complex challenges, I have nurtured an integrated research, design, and development team that brings interactive, and playful experiences to market. I have helped clients enhance workplace culture, championed responsible digital design, inspired underrepresented students to pursue careers in STEM, and supported organizations as they adopted circular economy practices.

I have shared my passion for play at SXSW, The Delight Conference, The Culture Summit, and in numerous podcasts and articles. Prior to IDEO, I designed  toys at VTech and University Games, and held lead product roles at thredUP and ShopWell.

A former Aspen Institute First Movers Fellow, I now have the privilege of guiding cohorts of corporate social entrepreneurs through the program as a member of the design team. As an educator, I have taught undergraduate design classes at Stanford University, and served as co-instructor for IDEO U’s “Creative Thinking for Complex Problem Solving” course. I hold a BS in Mechanical Engineering and an MS in the joint program in Design from Stanford University.